Madrigal Pharmaceuticals

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a pioneering biopharmaceutical company dedicated to the development of innovative therapies for patients with serious diseases. Our primary focus is on addressing unmet medical needs in the field of metabolic and liver diseases, particularly non-alcoholic steatohepatitis (NASH). We leverage cutting-edge science and technology to create novel drug candidates that have the potential to transform patient care.

At Madrigal, we are committed to advancing our lead product candidate, MGL-3196, which is currently in clinical trials. This oral therapy aims to improve liver health and metabolic function in patients suffering from NASH. Our research is driven by a team of experienced scientists and industry professionals who are passionate about making a difference in the lives of patients.

We believe in a patient-centric approach, ensuring that our developments are aligned with the needs and preferences of those we serve. Our vision is to become a leader in the biopharmaceutical industry by delivering safe and effective treatments that enhance the quality of life for patients worldwide.

• Core Values: Innovation, Integrity, and Patient Focus.
• Headquarters: Located in the UK, we operate in a collaborative environment that fosters creativity and scientific excellence.
• Future Goals: To expand our pipeline and explore new therapeutic areas while maintaining our commitment to high-quality research and development.

As we move forward, Madrigal Pharmaceuticals remains steadfast in our mission to provide hope and healing through groundbreaking therapies. We invite you to join us on this journey towards a healthier future.